Impressive results have been achieved by adoptively transferring T-cells expressing CD19-specific CARs with binding domains from murine mAbs to treat B-cell malignancies. T-cell mediated immune ...
Effectiveness and safety outcomes in patients with EBV+ PTLD treated with allogeneic EBV-specific T-cell immunotherapy (tabelecleucel) under an expanded access program (EAP) in Europe. This is an ASCO ...
A new chimeric antigen receptor (CAR) T cell therapy may help curb the problem of frequent relapse in patients with relapsed/refractory B-cell acute lymphoblastic leukemia. A new type of chimeric ...
The effect of trastuzumab on pCR in locally advanced HER2-positive breast cancer. Background: Trastuzumab has been proven to be effective in the immunotherapy for Her-2/neu-positive breast cancer.
Chinese scientists reveal the feasibility, tolerability, and efficacy of BCMA-CD19 bispecific CAR T-cells for treating chronic inflammatory demyelinating polyneuropathy (CIDP) and highlight the ...
Schematic illustration explaining the working principle of BCMA-CD19 bispecific CAR T cells used in current study. CD19 is the pan B cell marker but not expressed in long-lived plasma cells and BCMA ...
To avoid the problems of CD19-specific agents relying on effector cells, we aimed here for an agent employing an effector-cell-independent mechanism of action. In certain therapeutic settings, ...
Chimeric antigen receptor (CAR) T-cell therapy has matured rapidly. What used to be the “drug of the future” is suddenly the “drug of the now.” The first CAR T-cell therapeutic, Kymriah, was approved ...
Chimeric antigen receptor (CAR) T cell-based therapy has greatly improved cancer treatment, especially for hematologic cancers. 1 By providing T cells with synthetic receptors that target tumor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results